![]() CSPCY 1 month ago Announced | Other | $0.05 Per Share |
![]() CSPCY 8 months ago Paid | Other | $0.08 Per Share |
![]() CSPCY 3 Jun 2024 Paid | Other | $0.07 Per Share |
![]() CSPCY 7 Sep 2023 Paid | Other | $0.07 Per Share |
![]() CSPCY 5 Jun 2023 Paid | Other | $0.06 Per Share |
26 May 2025 Date | | - Cons. EPS | - EPS |
18 Mar 2025 Date | | - Cons. EPS | - EPS |
28 Nov 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2024 Date | | - Cons. EPS | - EPS |
27 May 2024 Date | | - Cons. EPS | - EPS |
![]() CSPCY 1 month ago Announced | Other | $0.05 Per Share |
![]() CSPCY 8 months ago Paid | Other | $0.08 Per Share |
![]() CSPCY 3 Jun 2024 Paid | Other | $0.07 Per Share |
![]() CSPCY 7 Sep 2023 Paid | Other | $0.07 Per Share |
![]() CSPCY 5 Jun 2023 Paid | Other | $0.06 Per Share |
26 May 2025 Date | | - Cons. EPS | - EPS |
18 Mar 2025 Date | | - Cons. EPS | - EPS |
28 Nov 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2024 Date | | - Cons. EPS | - EPS |
27 May 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Cuilong Zhang CEO | OTC PINK Exchange | 12591J207 Cusip |
CN Country | 21,400 Employees | 5 Jun 2025 Last Dividend | 16 Nov 2020 Last Split | - IPO Date |
CSPC Pharmaceutical Group Limited, established in 1992 and headquartered in Shijiazhuang, the People's Republic of China, is a prominent investment holding company specializing in the pharmaceutical sector. The company stands out for its comprehensive involvement in researching, developing, manufacturing, and distributing pharmaceutical products across a wide geographical stretch that includes the People's Republic of China, other Asian regions, North America, Europe, and beyond in the global market. Operating through its strategic divisions—Finished Drugs, Bulk Products, and Functional Food and Others—CSPC Pharmaceutical has cemented its reputation as a leading provider of a variety of pharmaceutical solutions. A significant milestone in the company's history is its strategic partnership with Pfizer Inc., aimed at launching a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, showcasing its commitment to contributing to global health crises solutions. Originally known as China Pharmaceutical Group Limited, the company rebranded to CSPC Pharmaceutical Group Limited in March 2013 to better reflect its expansive scope and ambitions.